CN113508840A

CN113508840A - Application of milk fat globule membrane in preparing milk powder for pregnant women

Info

Publication number: CN113508840A
Application number: CN202010276485.2A
Authority: CN
Inventors: 陈历俊; 赵军英; 张珍珍; 房新平; 乔为仓; 李晓旭; 刘斌; 刘彦品; 周伟明
Original assignee: Beijing Sanyuan Foods Co Ltd
Current assignee: Beijing Sanyuan Foods Co Ltd
Priority date: 2020-04-09
Filing date: 2020-04-09
Publication date: 2021-10-19
Also published as: WO2021204256A1

Abstract

The embodiment of the invention relates to an application of a milk fat globule membrane in preparing pregnant woman milk powder, and the pregnant woman milk powder added with the milk fat globule membrane can have one or more of the following properties: (1) can promote the growth and development of the infants born by the pregnant women after birth; (2) can promote the digestive tract of the infant born by the pregnant woman to mature after birth and improve the intestinal mucosa function of the infant born by the pregnant woman; (3) can regulate the flora structure of the infant born by the pregnant woman after birth; (4) can improve the health condition of pregnant women; (5) can improve the nutrient status of umbilical cord blood of pregnant women.

Description

Application of milk fat globule membrane in preparing milk powder for pregnant women

Technical Field

The invention relates to the field of food, in particular to application of a milk fat globule membrane in preparation of milk powder for pregnant women.

Background

The later stage of pregnancy is the key period of fetal development, and about two thirds of the growth and development of the fetus are concentrated in the later stage of pregnancy. If the nutrition of the mother is insufficient at this stage, the health of the mother and the fetus is seriously affected.

Milk Fat Globule Membrane (MFGM) is an important class of substances found in breast Milk, the formation of MFGM is closely related to the process of Milk Fat secretion in breast Milk, and Milk Fat globules are released from mammary gland cells to breast Milk, and are surrounded by three phospholipid layers when passing through the cell Membrane, and such three phospholipid layers are collectively called MFGM. The formation of MFGM allows the membrane-bound proteins, carbohydrates and lipids on the mother's own cell surface to be collected and transferred into breast milk. In breast milk, the content of the key component (sphingomyelin) of MFGM is 50-133 mg/L. The MFGM is produced by the mother's transfer of some of the nutrients in the mother's body to the baby through breast milk. The main components of MFGM are various phospholipids and special membrane proteins, which have the functions of supporting brain development, helping babies to regulate cognition and behavior, enhancing immunity, improving intestinal tracts and the like.

In the prior art, the milk fat globule membrane is mainly used for being added into infant milk powder.

The information disclosed in this background section is only for enhancement of understanding of the general background of the invention and should not be taken as an acknowledgement or any form of suggestion that this information forms the prior art already known to a person skilled in the art.

Disclosure of Invention

Object of the Invention

The invention aims to provide application of a milk fat globule membrane in preparing milk powder for pregnant women.

Solution scheme

In order to achieve the purpose of the invention, the embodiment of the invention provides the following technical scheme:

an application of milk fat globule membrane in preparing milk powder for pregnant women is provided.

Milk powder for pregnant women is prepared by adding milk fat globule membrane into the formula.

The above-described use, pregnant milk powder, in one possible implementation, has one or more of the following properties: (1) can promote the growth and development of the infants born by the pregnant women after birth; (2) can promote the digestive tract of the infant born by the pregnant woman to mature after birth and improve the intestinal mucosa function of the infant born by the pregnant woman; (3) can regulate the flora structure of the infant born by the pregnant woman after birth; (4) can improve the health condition of pregnant women; (5) can improve the nutrient status of umbilical cord blood of pregnant women.

The application and the pregnant woman milk powder in one possible implementation mode can promote the growth and development of the infant produced by the pregnant woman after birth, wherein the growth and development of the infant comprise one or more of the following components: promoting the weight gain of the infant and improving the daily gain of the infant.

The application and the pregnant woman milk powder in one possible implementation mode can promote the digestive tract maturation of the infant produced by the pregnant woman after birth and improve the intestinal mucosa function of the infant produced by the pregnant woman, and the application and the pregnant woman milk powder comprise one or more of the following components: the absorption area of the digestive tract of the infant is enlarged, the mechanical barrier of the intestinal tract of the infant is enhanced, and the expression level of the intestinal mucosa cytokine of the infant is improved.

The application and the pregnant woman milk powder can regulate the flora structure of the infant produced by the pregnant woman after birth, including one or more of the following: improving the diversity of intestinal microorganisms of infants and improving the abundance of beneficial flora.

The application and the pregnant woman milk powder can improve the health condition of pregnant women and comprise one or more of the following components in one possible implementation mode: increasing globulin concentration, creatine kinase concentration, total cholesterol concentration, low density lipoprotein cholesterol concentration, and non-esterified fatty acid concentration in blood plasma of pregnant woman in late gestation period.

The application and the pregnant woman milk powder can improve the nutrient state of umbilical cord blood of the pregnant woman in a possible implementation mode, and the nutrient state comprises one or more of the following components: increasing the blood sugar level, immunoglobulin A level, growth hormone level and non-esterified fatty acid level of umbilical cord blood of pregnant women.

In one possible implementation mode of the application and the pregnant woman milk powder, the pregnant woman milk powder is used in the later stage of pregnancy.

In a possible implementation mode of the application and the pregnant woman milk powder, the daily intake of the milk fat globule membrane in the pregnant woman milk powder is 10 g/kg/d.

Advantageous effects

The embodiment of the invention provides application of a milk fat globule membrane in preparing pregnant woman milk powder, and the pregnant woman milk powder added with the milk fat globule membrane can have one or more of the following properties: (1) can promote the growth and development of the infants born by the pregnant women after birth; (2) can promote the digestive tract of the infant born by the pregnant woman to mature after birth and improve the intestinal mucosa function of the infant born by the pregnant woman; (3) can regulate the flora structure of the infant born by the pregnant woman after birth; (4) can improve the health condition of pregnant women; (5) can improve the nutrient status of umbilical cord blood of pregnant women.

Drawings

One or more embodiments are illustrated by the corresponding figures in the drawings, which are not meant to be limiting. The word "exemplary" is used exclusively herein to mean "serving as an example, embodiment, or illustration. Any embodiment described herein as "exemplary" is not necessarily to be construed as preferred or advantageous over other embodiments.

In the following figures, CON represents a control group, and MFGM represents an experimental group.

FIG. 1A is a graph comparing the concentration of DAO in piglets of the experimental group and piglets of the control group in example 4 of the present invention;

FIG. 1B, FIG. 1C, FIG. 1D are the expression levels of mRNA of different relevant cytokines in ileal mucosa of experimental piglets and control piglets in example 4 of the present invention; FIG. 1E, FIG. 1F, FIG. 1G show the expression levels of mRNA of different related cytokines in colonic mucosa of piglets of experimental group and piglets of control group in example 4 of the present invention.

FIGS. 2A, 2B and 2C are the analysis of fecal flora 16s at PCoA, phylum and genus levels in the experimental group of sows at day 114 of gestation; fig. 2D, 2E, and 2F are fecal flora 16s analyses at PCoA, phylum, and genus levels for 21-day-old experimental group piglets, respectively.

FIG. 3A is an Ulweighed-Unifrac-based difference analysis between wilcoxon groups for sows; FIG. 3B is an Ulweighed-Unifrac-based difference analysis between wilcoxon groups for piglets.

FIG. 4A is a graph showing the results of analyzing the correlation of the genus Difference with physiological parameters of sows; FIG. 4B is a graph of the results of an analysis of the correlation between key bacterial species in piglet feces and an indicator of differential expression in the colonic intestinal barrier.

Detailed Description

In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are a part of the embodiments of the present invention, but not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.

Furthermore, in the following detailed description, numerous specific details are set forth in order to provide a better understanding of the present invention. It will be understood by those skilled in the art that the present invention may be practiced without some of these specific details. In some embodiments, materials, elements, methods, means, and the like that are well known to those skilled in the art are not described in detail in order to not unnecessarily obscure the present invention.

Throughout the specification and claims, unless explicitly stated otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or component but not the exclusion of any other element or component.

The embodiment of the invention adopts the following experimental method:

(1) group setting: 22 large long white sows are selected and randomly divided into two groups: the age and weight of the sows in the control group (n-11) and the experimental group (n-11) were not significantly different.

(2) Experimental methods and results

Control group: the basic diet is adopted, and the common corn and soybean meal daily ration is fed every day.

Experimental groups: feeding common corn bean pulp daily ration by adopting basic diet 79 days before pregnancy; feeding the corn soybean meal daily ration added with the MFGM from 80 th day of pregnancy until parturition, adding the MFGM serving as a functional ingredient into the common corn soybean meal daily ration according to the MFGM serving amount of 10 g/kg/day for feeding sows of an experimental group, and only adopting basic diet instead of adding the MFGM serving as the functional ingredient after the sows are produced.

Example 1 Effect of post-pregnancy supplementation with MFGM on Pre-weaning growth and development of piglets

After birth, average body weights of the piglets of the control group and the experimental group on the day of birth, and on the 7 th, 14 th and 21 st days, and daily gains on the 0 th to 7 th, 7 th to 14 th and 14 th to 21 st days after birth are respectively recorded, and the average individual weights of the piglets of the experimental group on the 7 th, 14 th and 21 st days after birth are all found to be higher than those of the control group, wherein the significant difference (P < 0.05) is achieved on the 14 th and 21 st days. In addition, the average daily gain of piglets in the experimental group was also significantly higher than in the control group within 3 weeks after birth, with significant differences (p < 0.05) being achieved between the average daily gains on days 0-7 and 7-14. The effects of the post-pregnancy supplementation of MFGM on the growth and development of piglets before weaning (0-21 days after delivery) are shown in table 1. The above average body weight and daily average gain data indicate that the post-natal growth and development of piglets can be significantly improved by only supplementing MFGM in the later stage of pregnancy.

TABLE 1 Effect of late gestation supplementation with MFGM on piglet growth performance over 0-21 days

Indicates that the experimental group has significant difference compared with the control group, and P is less than 0.05.

Table 1 shows that the supplement of MFGM in the later period of pregnancy has the effect of promoting the growth and development of piglets before weaning.

Example 2 Effect of post-pregnancy supplementation with MFGM on intestinal villi morphology in 21-day-old piglets

MFGM is supplemented in the later stage of pregnancy, and the influence on the intestinal villus form of the 21-day-old piglets is observed by adopting a method of statistical observation under a microscope after tissue section HE staining, and the result is shown in Table 2. On the 21 st day after the birth of the piglets, the height of the villus in the jejunum of the piglets in the experimental group is obviously higher than that in the control group (P < 0.05), the crypt depth of the duodenum and the jejunum is obviously lower than that in the control group (P < 0.05), and the ratio of the height of the villus in the duodenum and the jejunum to the crypt depth is obviously higher than that in the control group (P < 0.05). The higher the villus height in intestinal tracts of piglets, the lower the crypt depth, and the higher the ratio of the villus height to the crypt depth, which indicates that the larger the digestive absorption area in the intestinal tracts is, the more the intestinal tracts can help the piglets to absorb nutrients and promote the piglets to grow and develop. The intestinal villus morphology data show that the digestive tract absorption area of the piglets after birth can be remarkably improved by only supplementing MFGM in the later period of pregnancy.

TABLE 2 Effect of post-pregnancy supplementation of MFGM on intestinal villi morphology of 21-day-old piglets

Indicates that the experimental group has significant difference compared with the control group, and P is less than 0.05; indicates that the experimental group has significant difference compared with the control group, and P is less than 0.01.

Example 3 Effect of late gestation MFGM addition on intestinal Short Chain Fatty Acids (SCFA) in piglets at 114 and 21 days of age in sows

Short Chain Fatty Acids (SCFAs) refer to fatty acids with a carbon number of not more than 6, which are high in the intestinal tract as acetic, propionic and butyric acids, which are present in the form of acetates, propionates and butyrates. In vivo, SCFAs have a variety of important biological functions, such as providing energy, modulating immunity, regulating intestinal cell metabolism, maintaining water electrolyte balance, and improving intestinal flora structure. MFGM is added in the later gestation period, and the influence on intestinal short-chain fatty acid (SCFA) of piglets at the 114 th day and the 21 th day of gestation of the sows is examined by adopting a metabonomics method, and the result is shown in a table 3. The concentrations of acetate, propionate and butyrate in the feces of the sows in the experimental group are all obviously higher than those in the control group (p < 0.05). Comparing the short-chain fatty acid salt concentration of the feces in the ileum and colon of the piglets, the propionate concentration in the ileum of the piglets in the experimental group is obviously higher than that in the control group (p < 0.05). The short-chain fatty acid data show that the addition of MFGM only in the later stage of pregnancy can not only obviously improve the content of the short-chain fatty acid in the intestinal tract of the pregnant sow, but also influence the intestinal microenvironment of the postnatal piglets in the abdomen, particularly the content of the short-chain fatty acid in the ileum, and change the growth and development, the immunoregulation, the flora structure and the like of the piglets.

TABLE 3 SCFA effect of late gestation MFGM addition on piglets at 114 and 21 days of age in sows

Example 4 Effect of daily ration addition of MFGM in late gestation period in sows on mRNA expression of relevant cytokines on intestinal mucosa of newborn 21-day-old piglets

Diamine oxidase (DAO) is a highly active intracellular enzyme in the villi in the upper layer of the small intestinal mucosa of human and mammals, plays a role in histamine and various polyamine metabolism, and can reflect the integrity and damage degree of the intestinal mechanical barrier, and compared with the control group, the DAO level of piglets in the experimental group is remarkably reduced compared with the control group by analyzing the diamine oxidase level and related gene expression between the experimental group and the control group to compare the intestinal barrier function difference (fig. 1A).

In addition, the expression level of mRNA of related cytokines on intestinal mucosa of piglets between the experimental group and the control group was analyzed, and the relative expression amount of mRNA of ZO-1, Mucin-20 and TLR2 in ileal mucosa of piglets in the experimental group was also significantly increased (FIG. 1B-D) (P < 0.05). In addition, the gene expression levels of Ocplus, Ocplus-1, Ocplus-2, Ocplus-4, ZO-1, Mucin-2, Mucin-4, Mucin-13, TNF-alpha, IFN-gamma, IL-22, TLR2 and TLR-4 of the colon cells of the piglets in the experimental group are also significantly higher than those in the control group (FIG. 1E-G) (P < 0.05). Namely, compared with a control group, the expression level of related cytokine mRNA on various intestinal mucosa of the piglets in the experimental group is obviously increased. The combination of the intestinal morphology structure data in example 2, i.e. a significant increase in villus height in the jejunum, a significant decrease in crypt depth in the duodenum and jejunum, and a significant increase in the relative mRNA expression levels of occludin, claudin-1,2,4, ZO-1, mucin (

mucin

2,4,13 and 20) and immune-related cytokines (TNF- α, INF- γ, IL-22, TLR2 and TLR4) indicate that MFGM has a beneficial effect on piglet intestinal mucosal function both at the intestinal morphology and gene level.

Example 5 structural analysis of flora

The fecal flora analysis of piglets at 114 th and 21 th day of gestation was performed for 16s (fig. 2A-F), respectively, and it can be seen that the intestinal microecology of sows is significantly different from that of piglets. From the comparison of flora structures, as the intestinal tract of the piglets is not completely developed, the intestinal flora is not mature, and the flora structure of the sows is completely established and is a mature system. Therefore, the difference of the floras of the sows and the piglets is very obvious from the aspects of the floras abundance and the varieties. However, from the genetic point of view, the flora of the piglets is mainly obtained from the mother through the ways of taking breast milk and the like, and the microbes of the mother can also be inherited to the offspring, so the flora of the sow is very important for the establishment of the flora of the piglets.

Among the intestinal flora of sows, Firmicutes and Bacteroidetes are the largest two phyla, followed by Proteobacteria and spirulina (spirochaetes); on the genus level, Ruminococcus _ UCG-005, Norank _ f __ Muribacterae, Ruminococcus _ NK4A214_ group are the main genera. Based on the difference analysis among wilcoxon groups of Unweighted-Unifrac, the abundance of Prevotella in the feces of the sows in the experimental group was significantly higher than that in the control group (P < 0.05), while the abundance of Norank _ f __ Murebacteriaceae and Lachnospiraceae _ XPB1014_ group was lower than that in the control group (P < 0.05) (FIG. 3A).

And (3) analyzing the correlation between the differential bacteria of the sow and the physiological parameters, namely performing correlation analysis on the obtained differential bacteria, metabolites and genes. And (3) sow: prevotella bacteria positively correlate with the expression levels of GH (R.equal to 0.693, P < 0.05), NEFA (R.equal to 0.758, P < 0.05), TC (R.equal to 0.673, P < 0.05) and LDL (R.equal to 0.783, P < 0.05)). The addition of MFGM increases the abundance of Prevotella, which is significantly correlated with increased reproductive performance and fatty acid synthesis, and with plasma and GH concentrations in cord blood. The above data demonstrate that supplementation with MFGM can modulate gut flora and promote host health. Norank _ f __ Muribacteae is negatively associated with TC (R ═ 0.648, P < 0.05), LDL (R ═ 0.640, P < 0.05) and IgA (R ═ 0.717, P < 0.05) expression. Lachnospiraceae _ XPB1014_ group is negatively correlated with GH (R ═ 0.827, P < 0.05), NEFA (R ═ 0.648, P < 0.05), TC (R ═ 0.685, P < 0.05), LDL (R ═ 0.762, P < 0.05) concentrations (fig. 4A).

In intestinal flora of piglets, alpha-diversity analysis shows that Sobs, Shannon, Simpson, Ace and Chao indexes of the experimental piglet fecal flora are obviously higher than those of a control group (P is less than 0.05), which indicates that the experimental group can obviously improve the diversity of intestinal microorganisms of the piglets. The microbial community structures of the experimental group and the control group are significantly different based on the wilcoxon analysis of Unweighted-Unifrac (R is 0.728, P is less than 0.05). Differential analysis of flora at genus level showed that the expression abundance of Christenseella faecalis-R-7-group, Alloprevilla and unclassified-f __ lachnospiraceae in the feces of piglets in the experimental group was significantly higher than that in the control group (P < 0.05) (FIG. 3B). Previous studies have shown that Christensenlaceae _ R-7_ group is very beneficial to intestinal health and has high heritability. Therefore, the increased expression abundance of Christensenlaceae _ R-7_ group in intestinal tracts of experimental piglets contributes to improving the growth performance of the experimental piglets. Christenseellaceae _ R-7_ group is considered to be a butyrate producer, playing a key role in the intestinal environment and immune regulation. Butyrate has been reported to induce relative mRNA expression and its secretion in goblet cells and promote protein assembly.

We analyzed the correlation between key bacterial species in piglet feces and differentially expressed indicators in the colonic intestinal barrier. Christenseella acid _ R-7_ group is positively correlated with the mRNA relative expression of occludin (R ═ 0.855, P < 0.05), mucin _13(R ═ 0.818, P < 0.05), TLR4(R ═ 0.927, P < 0.05), claudin-2(R ═ 0.855, P < 0.05), IL-22(R ═ 0.721, P < 0.05), GPR43(R ═ 0.0.661, P < 0.05), claudin-1(R ═ 0.700, P < 0.05) and TLR2(R ═ 0.661, P < 0.05). Alloprevotella is positively correlated with the gene expression of occludin (R ═ 0.855, P < 0.05), mucin 13(R ═ 0.806, P < 0.05), TLR4(R ═ 0.891, P < 0.05), claudin-2(R ═ 0.669, P < 0.05), IL-22(R ═ 0.697, P < 0.05), claudin-4(R ═ 0.663, P < 0.05), INF- γ (R ═ 0.636, P < 0.05) and TLR2(R ═ 0.576, P < 0.05). Unclasied _ f __ Lachnospiraceae was positively correlated with occlusin (R ═ 0.915, P <0.001), mucin 13(R ═ 0.721, P < 0.05), TLR4(R ═ 0.733, P < 0.05), claudin-2(R ═ 0.644, P < 0.05), IL-22(R ═ 0.685, P < 0.05), claudin-4(R ═ 0.693, P < 0.05), IFN- γ (R ═ 0.927, P < 0.05), claudin-1(R ═ 0.782, P < 0.05) and TLR2(R ═ 0.818, P < 0.05) (fig. 4B).

The gut flora also interacts with the host through its metabolites (mainly comprising SCFAs) and plays an important role in antioxidant, anti-inflammatory, gut balance. The propionate concentration in the MFGM piglet's ileal chyme, GPR41 expression in the ileal mucosa, and GPR43, GPR119, GPR120 expression in the colonic mucosa were significantly higher than in the control group. SCFAs can activate signal transduction pathways by binding to GPR on the cell surface to mediate an immune response. Increased relative mRNA expression of GPR in MFGM piglets may enhance the binding capacity of intestinal epithelial cells to SCFA, thereby further modulating immune function and improving intestinal barrier. This explains why expression of immune-related cytokines is increased in the intestinal barrier of MFGM piglets. Therefore, the supplement of MFGM in the later period of pregnancy can improve the intestinal function and the micro-ecology, thereby improving the growth performance of the newborn piglets.

Example 6 Effect of the addition of MFGM in the sow's diet in the late gestation period on reproductive Performance

The effects of MFGM supplementation on sow reproductive performance including total born piglets, live piglets, healthy piglets, weak piglets, stillbirth number, litter birth weight, average individual birth weight, and variation in litter birth weight at the later stage of pregnancy are shown in table 1. As can be seen from Table 1, the addition of MFGM to the ration in the later stage of pregnancy has no significant effect on the reproductive performance. The total production piglets, the live piglets, the healthy piglets, the weak piglets, the number of the dead piglets, the litter birth weight, the average individual birth weight and the variation of the litter birth weight of the piglets in the control group and the experimental group have no obvious difference. However, the number of dead tires in the experimental group tended to decrease compared to the control group (table 4).

TABLE 4 influence of daily ration addition of MFGM to sows in late gestation on their reproductive performance

Variation of the initial weight in the litter, i.e. the standard deviation of the weight of the newborn piglets from the mean weight.

Example 7 Effect of daily ration addition of MFGM in sows at the late stage of gestation on plasma parameters at day 114 of gestation

The effect of MFGM supplementation on plasma parameters on day 114 of gestation in the latter gestation period is shown in table 5. As shown in table 5, the meg supplement had no significant effect on plasma Total Protein (TP), Globulin (GLB) concentration, and albumin/globulin ratio (ALB/GLB) (P >0.05), but significantly increased Albumin (ALB) and Creatine Kinase (CK) concentrations (P < 0.05). ALB plays an important role in maintaining blood pressure and nutrition balance, and the ALB concentration of the MFGM group is beneficial to the health of the sow.

In addition, MFGM significantly increased the Total Cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) levels in sow plasma, but there was no significant difference in total triglyceride TG, high density lipoprotein cholesterol (HDL) and very low density lipoprotein cholesterol (VLDL-C) between the two groups. The concentration of blood Glucose (GLU) and Total Bile Acid (TBA) was not significantly different in the two groups, but the concentration of non-esterified fatty acids (NEFA) was higher in the experimental group than in the control group (P < 0.05). Increased concentrations of LDL-C and NEFA indicate increased rates of fatty acid synthesis in vivo, helping to maintain homeostasis.

TABLE 5 influence of daily ration addition of MFGM to sows in late gestation on their plasma parameters at day 114 of gestation

Example 8 Effect of post-pregnancy supplementation with MFGM on plasma parameters of cord blood at parturition

Post-pregnancy supplementation with MFGM analysis of plasma parameters of cord blood at delivery is shown in table 6. The blood Glucose (GLU), immunoglobulin A (IgA), Growth Hormone (GH) and non-esterified fatty acid NEFA levels were all significantly higher in the experimental group than in the control group (p < 0.05). Cord blood is the main route by which the fetus absorbs nutrients from the mother, GH is essential for the growth and development of the fetus, and IgA in cord blood is essential for intestinal development and immune maturation after birth. In addition, the concentration of GLU and NEFA in umbilical cord blood increases. As explained above, sows in the MFGM group can provide more nutrition to the fetus.

TABLE 6 Effect of late pregnancy supplementation with MFGM on cord plasma parameters at parturition

Finally, it should be noted that: the above examples are only intended to illustrate the technical solution of the present invention, but not to limit it; although the present invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some technical features may be equivalently replaced; and such modifications or substitutions do not depart from the spirit and scope of the corresponding technical solutions of the embodiments of the present invention.

Claims

1. An application of milk fat globule membrane in preparing milk powder for pregnant women is provided.

2. The milk powder for pregnant women is characterized in that: the formula of the cream is added with a cream ball membrane.

3. Use according to claim 1, characterized in that: the pregnant woman milk powder has one or more of the following properties: (1) can promote the growth and development of the infants born by the pregnant women after birth; (2) can promote the digestive tract of the infant born by the pregnant woman to mature after birth and improve the intestinal mucosa function of the infant born by the pregnant woman; (3) can regulate the flora structure of the infant born by the pregnant woman after birth; (4) can improve the health condition of pregnant women; (5) can improve the nutrient status of umbilical cord blood of pregnant women.

4. Use according to claim 1, characterized in that: the infant capable of promoting the growth and development of the pregnant woman after birth comprises one or more of the following components: promoting the weight gain of the infant and improving the daily gain of the infant.

5. Use according to claim 1, characterized in that: the composition can promote the digestive tract maturation of the infant born by the pregnant woman after birth and improve the intestinal mucosa function of the infant born by the pregnant woman and comprises one or more of the following components: the absorption area of the digestive tract of the infant is enlarged, the mechanical barrier of the intestinal tract of the infant is enhanced, and the expression level of the intestinal mucosa cytokine of the infant is improved.

6. Use according to claim 1, characterized in that: the bacteria colony structure capable of regulating the birth of the infant born by the pregnant woman comprises one or more of the following: improving the diversity of intestinal microorganisms of infants and improving the abundance of beneficial flora.

7. Use according to claim 1, characterized in that: the health condition of pregnant women can be improved by one or more of the following: increasing globulin concentration, creatine kinase concentration, total cholesterol concentration, low density lipoprotein cholesterol concentration, and non-esterified fatty acid concentration in blood plasma of pregnant woman in late gestation period.

8. Use according to claim 1, characterized in that: the nutrient state of the umbilical cord blood of the pregnant woman can be improved by one or more of the following components: increasing the blood sugar level, immunoglobulin A level, growth hormone level and non-esterified fatty acid level of umbilical cord blood of pregnant women.

9. Use according to claim 1, characterized in that: the pregnant woman milk powder is used in the later period of pregnancy.

10. Use according to claim 1, characterized in that: the daily intake of the milk fat globule membrane in the milk powder for pregnant women is 10 g/kg/d.